Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study ACCESS Newswire - Mon Mar 30, 4:00AM CDT

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose -

REVB : 1.2500 (+1.63%)
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference ACCESS Newswire - Tue Mar 24, 4:00AM CDT

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference ACCESS Newswire - Thu Mar 19, 4:00AM CDT

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 ACCESS Newswire - Thu Feb 26, 10:15AM CST

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 ACCESS Newswire - Mon Jan 26, 3:55AM CST

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds ACCESS Newswire - Fri Jan 23, 8:10AM CST

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI ACCESS Newswire - Wed Jan 21, 2:30AM CST

- Single Phase 2/3 Adaptive Study Design -

REVB : 1.2500 (+1.63%)
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) ACCESS Newswire - Wed Jan 14, 3:00AM CST

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study -

REVB : 1.2500 (+1.63%)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACCESS Newswire - Mon Jan 12, 11:00AM CST

SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development ACCESS Newswire - Wed Jan 7, 3:00AM CST

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation,...

REVB : 1.2500 (+1.63%)

Barchart Exclusives

Sysco Just Announced a $29.1 Billion Acquisition and Wall Street Is Nervous. Can a 3% Dividend Sweeten the Deal? Barchart - Thu Apr 2, 6:30PM CDT
The Jetro deal strategically pushes Sysco into a faster‑growing, higher‑margin channel, but the new debt, jumping leverage, share dilution, and negative S&P outlook explain why SYY stock just had its worst day since 2020. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.